Tackling Cardiovascular Disease with Heart
Cardurion is a next-generation cardiovascular company that is taking a bold and innovative approach to addressing the unmet needs of people suffering from and at risk of heart disease. While there have been recent advances in the treatment of cardiovascular disease, heart disease remains the leading cause of death in the United States, and nearly half of all adults in this country have one or more heart-related conditions.1
Cardurion is at the forefront of discovering desperately needed new approaches to treating heart disease. We were founded by physician-scientists who possess world-class expertise in cardiovascular signaling pathways, and we couple this expertise with a shared passion to find and develop a pipeline of novel treatment options to improve the lives of our patients.
Cardurion already has two groundbreaking clinical programs in development, a PDE9 inhibitor program targeting heart failure, and the first-ever CaMKII inhibitor in clinical development targeting multiple CV indications. We are singularly committed to one purpose: changing the course of cardiovascular disease for patients.
